These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19373666)

  • 1. Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
    Basile FG
    Leuk Lymphoma; 2009 Apr; 50(4):653-5. PubMed ID: 19373666
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
    Lancet JE; List AF; Moscinski LC
    Leukemia; 2007 Mar; 21(3):586-8. PubMed ID: 17230228
    [No Abstract]   [Full Text] [Related]  

  • 3. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
    Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
    Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
    [No Abstract]   [Full Text] [Related]  

  • 4. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
    Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M
    Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011
    [No Abstract]   [Full Text] [Related]  

  • 5. How I treat patients with myelodysplastic syndromes.
    Stone RM
    Blood; 2009 Jun; 113(25):6296-303. PubMed ID: 19383969
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenalidomide-induced durable hematological and cytogenetic remission in del(5q)-associated de novo acute myeloid leukemia.
    Hussein K; Tefferi A
    Leuk Res; 2009 Aug; 33(8):e132-3. PubMed ID: 19304324
    [No Abstract]   [Full Text] [Related]  

  • 7. Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.
    Todaro J; Bollmann PW; Rother ET; del Giglio A
    Sao Paulo Med J; 2015; 133(3):271-4. PubMed ID: 25250799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.
    Adès L; Eclache V; Gardin C; Boehrer S; Leroux G; Martiat P; Fenaux P
    Bone Marrow Transplant; 2010 Apr; 45(4):791-2. PubMed ID: 19718061
    [No Abstract]   [Full Text] [Related]  

  • 9. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
    Mesa RA; Tefferi A; Li CY; Steensma DP
    Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
    [No Abstract]   [Full Text] [Related]  

  • 10. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
    Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
    Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
    [No Abstract]   [Full Text] [Related]  

  • 11. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.
    Peñarrubia MJ; Silvestre LA; Conde J; Cantalapiedra A; Garcia Frade LJ
    Leuk Res; 2009 Jun; 33(6):e8-9. PubMed ID: 19168219
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current treatment options for myelodysplastic syndromes].
    Nolte F; Hofmann WK
    Dtsch Med Wochenschr; 2010 Sep; 135(38):1863-9. PubMed ID: 20842606
    [No Abstract]   [Full Text] [Related]  

  • 14. Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study.
    He J; Xiu L; De Porre P; Dass R; Thomas X
    Leuk Lymphoma; 2015 Apr; 56(4):1033-42. PubMed ID: 25098427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
    Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
    Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
    Pollyea DA; Zehnder J; Coutre S; Gotlib JR; Gallegos L; Abdel-Wahab O; Greenberg P; Zhang B; Liedtke M; Berube C; Levine R; Mitchell BS; Medeiros BC
    Haematologica; 2013 Apr; 98(4):591-6. PubMed ID: 23242596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
    Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
    Tefferi A; Lasho TL; Mesa RA; Pardanani A; Ketterling RP; Hanson CA
    Leukemia; 2007 Aug; 21(8):1827-8. PubMed ID: 17460705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.